Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Jiangling Peng, Mingjie Fan, Chelsea An, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 130, Iss. 4, pp. 439-456
Open Access | Times Cited: 180

Showing 1-25 of 180 citing articles:

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
Lili Yu, Wei Hong, Shen Lu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 82
Promising Nanocarriers to Enhance Solubility and Bioavailability of Cannabidiol for a Plethora of Therapeutic Opportunities
Lucia Grifoni, Giulia Vanti, Rosa Donato, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6070-6070
Open Access | Times Cited: 67
Statement on safety of cannabidiol as a novel food: data gaps and uncertainties
Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, et al.
EFSA Journal (2022) Vol. 20, Iss. 6
Open Access | Times Cited: 49
An update on animal models of intervertebral disc degeneration and low back pain: Exploring the potential of artificial intelligence to improve research analysis and development of prospective therapeutics
Mauro Alini, Ashish D. Diwan, W. Mark Erwin, et al.
JOR Spine (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 28
CB2 receptor in the CNS: From immune and neuronal modulation to behavior
Wanda Grabon, Sylvain Rheims, Jonathon Smith, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 150, pp. 105226-105226
Open Access | Times Cited: 28
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Grace Tsz Yan Yau, Waiting Tai, Jonathon C. Arnold, et al.
Pharmaceutical Research (2023) Vol. 40, Iss. 5, pp. 1087-1114
Open Access | Times Cited: 27
Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn’t
Catalina Christensen, Martin Rose, Claus Cornett, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2323-2323
Open Access | Times Cited: 27
Current Challenges and Opportunities for Improved Cannabidiol Solubility
Khondker R. Hossain, Amani Alghalayini, Stella M. Valenzuela
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14514-14514
Open Access | Times Cited: 27
Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database
Qin Zhou, Zhiqiang Du, Kankan Qu, et al.
Asian Journal of Psychiatry (2023) Vol. 90, pp. 103828-103828
Closed Access | Times Cited: 22
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 12
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples
Barry E. Gidal, Ryan G. Vandrey, Chela Wallin, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 11
Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing
Andrea J. Narayan, Luke A. Downey, Sarah Rose, et al.
Journal of Clinical Sleep Medicine (2024) Vol. 20, Iss. 5, pp. 753-763
Closed Access | Times Cited: 10
Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer’s Disease
Jordan P. Hickey, Andrila E. Collins, Mackayla L. Nelson, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 5, pp. 4379-4402
Open Access | Times Cited: 9
Characterizing Cannabidiol Use in a Breast Cancer Population
Nicole Fleege, Bradley T. Loeffler, Kevin F. Boehnke, et al.
Clinical Breast Cancer (2025)
Closed Access | Times Cited: 1
A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis
Maude Barbeau-Grégoire, Colombe Otis, Antoine Cournoyer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10384-10384
Open Access | Times Cited: 30
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review
Kuldeep Singh, Bharat Bhushan, Dilip Kumar Chanchal, et al.
Behavioural Neurology (2023) Vol. 2023, pp. 1-17
Open Access | Times Cited: 19
Effect of Genotype, Year, and Their Interaction on the Accumulation of Bioactive Compounds and the Antioxidant Activity in Industrial Hemp (Cannabis sativa L.) Inflorescences
Romina Beleggia, Valeria Menga, Flavia Fulvio, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8969-8969
Open Access | Times Cited: 18
A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders
Oluwadara Pelumi Omotayo, Yolandy Lemmer, Shayne Mason
Journal of Cannabis Research (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 6
CBD in the Treatment of Epilepsy
Kinga K. Borowicz-Reutt, Julia Czernia, Marlena Krawczyk
Molecules (2024) Vol. 29, Iss. 9, pp. 1981-1981
Open Access | Times Cited: 6
plantMASST - Community-driven chemotaxonomic digitization of plants
Paulo Wender Portal Gomes, Helena Mannochio-Russo, Robin Schmid, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Effects of Cannabinoids on Intestinal Motility, Barrier Permeability, and Therapeutic Potential in Gastrointestinal Diseases
K. J. CROWLEY, Łukasz Kiraga, Edyta Miszczuk, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6682-6682
Open Access | Times Cited: 6
Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models
Emma Puighermanal, Marta Luna‐Sánchez, Alejandro Gella, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
In utero exposure to cannabidiol disrupts select early-life behaviors in a sex-specific manner
Daniela Iezzi, Alba Cáceres-Rodríguez, Pascale Chavis, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze
Débora Cristina Niero Fabris, Milene Cristina de Carvalho, Marcus Lira Brandão, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 12, pp. 1371-1383
Open Access | Times Cited: 23
Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge
Alessandra Di Salvo, Maria Beatrice Conti, Giorgia Della Rocca
Frontiers in Veterinary Science (2023) Vol. 10
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top